Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting

#1244

Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s

Aim(s): We performed a retrospective analysis to evaluate medians(m) of progression free survival(PFS)and safety in metastatic pNET pts treated with everolimus in the real life setting

Materials and methods: Consecutive pts with progressive metastatic pNET treated at Gustave Roussy(Villejuif, France)from January 2006 to August 2014 with everolimus were analyzed. Primary end-points were mPFS. Secondary objective were mOS, best response according to Response Evaluation Criteria in Solid Tumor(RECIST v.1.1) and safety according to the National Cancer Institute Common Toxicity Criteria (CTCAE v.4.0)

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Del Prete M

Authors: Del Prete M, Malka L, Borget I, Berdelou A, Boige V,

Keywords: Pancreatic Neuroendocrine Tumor, Everolimus, Safety,

To read the full abstract, please log into your ENETS Member account.